Will Pfizer's gene therapy for Hemophilia A receive FDA approval by December 31, 2024? | Binary | | | 5 months ago | |
Will Pfizer's gene therapy for Hemophilia A be granted priority review by the FDA by October 31, 2024? | Binary | | | 5 months ago | |
Will Sangamo submit BLA for ST-920 by end of 2025? | Binary | | | 2 months ago | |
Will Sangamo achieve the first milestone payment in the Genentech deal by December 31, 2024? | Binary | | | 5 months ago | |
Will Sangamo announce a clinical trial for the tau-repressor therapy by June 30, 2025? | Binary | | | 5 months ago | |
Will Sangamo receive an additional $50 million in milestone payments from Genentech by August 6, 2025? | Binary | | | 5 months ago | |
How much will Sangamo Therapeutics receive in total milestone payments from Genentech by December 31, 2025? | Categorical | | | 5 months ago | |
Will Pfizer and Sangamo's Hemophilia A gene therapy be commercially launched by June 30, 2025? | Binary | | | 5 months ago | |
Will Pfizer's Hemophilia A gene therapy achieve more than $100 million in sales by December 31, 2025? | Binary | | | 5 months ago | |
Will Pfizer and Sangamo's Hemophilia A gene therapy be FDA approved by December 31, 2024? | Binary | | | 5 months ago | |
Will Pfizer's stock price increase by at least 10% by August 31, 2024, due to positive Phase 3 study results? | Binary | | | 5 months ago | |
Will FDA grant Accelerated Approval to ST-920 by end of 2026? | Binary | | | 2 months ago | |
Will Sangamo announce positive Phase 3 results for ST-920 by end of 2025? | Binary | | | 2 months ago | |
What will be the outcome of Sangamo's BLA for ST-920 by end of 2026? | Categorical | | | 2 months ago | |
How many competitors will enter Fabry gene therapy market by end of 2025? | Categorical | | | 2 months ago | |
How will Sangamo's stock react within a week of FDA's ST-920 decision? | Categorical | | | 2 months ago | |
How will Sangamo Therapeutics' stock price change by August 6, 2025, post-Genentech deal? | Categorical | | | 5 months ago | |
Which neurodegenerative condition will Sangamo and Genentech target first in their partnership by December 31, 2024? | Categorical | | | 5 months ago | |
What will be the market share of Pfizer and Sangamo's Hemophilia A gene therapy by December 31, 2025? | Categorical | | | 5 months ago | |
How will Pfizer's stock price react within one month after the commercial launch of the Hemophilia A gene therapy? | Categorical | | | 5 months ago | |
How many patients will be treated with Pfizer and Sangamo's Hemophilia A gene therapy by December 31, 2025? | Categorical | | | 5 months ago | |
What will be the impact of Pfizer's gene therapy for Hemophilia A on annual bleeding episodes in patients by December 31, 2025? | Categorical | | | 5 months ago | |
How many countries will approve Pfizer's gene therapy for Hemophilia A by December 31, 2025? | Categorical | | | 5 months ago | |
What will be the market share of Pfizer's gene therapy for Hemophilia A compared to existing treatments by December 31, 2025? | Categorical | | | 5 months ago | |
